- Home
- XBIO vs APRE Comparison
XBIO vs APRE Comparison
Compare XBIO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- APRE
- Stock Information
- Founded
- XBIO N/A
- APRE 2006
- Country
- XBIO United States
- APRE United States
- Employees
- XBIO N/A
- APRE N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XBIO Health Care
- APRE Health Care
- Exchange
- XBIO Nasdaq
- APRE Nasdaq
- Market Cap
- XBIO 5.9M
- APRE 6.9M
- IPO Year
- XBIO N/A
- APRE 2019
- Fundamental
- Price
- XBIO $2.54
- APRE $1.18
- Analyst Decision
- XBIO Hold
- APRE Strong Buy
- Analyst Count
- XBIO 1
- APRE 1
- Target Price
- XBIO N/A
- APRE $20.00
- AVG Volume (30 Days)
- XBIO 72.1K
- APRE 104.6K
- Earning Date
- XBIO 11-13-2025
- APRE 11-12-2025
- Dividend Yield
- XBIO N/A
- APRE N/A
- EPS Growth
- XBIO N/A
- APRE N/A
- EPS
- XBIO N/A
- APRE N/A
- Revenue
- XBIO $2,858,935.00
- APRE $488,239.00
- Revenue This Year
- XBIO $1.99
- APRE N/A
- Revenue Next Year
- XBIO $20.00
- APRE N/A
- P/E Ratio
- XBIO N/A
- APRE N/A
- Revenue Growth
- XBIO 13.30
- APRE N/A
- 52 Week Low
- XBIO $2.20
- APRE $1.15
- 52 Week High
- XBIO $13.93
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- XBIO 38.98
- APRE 36.04
- Support Level
- XBIO $2.51
- APRE $1.21
- Resistance Level
- XBIO $2.70
- APRE $1.25
- Average True Range (ATR)
- XBIO 0.20
- APRE 0.07
- MACD
- XBIO -0.04
- APRE -0.01
- Stochastic Oscillator
- XBIO 18.26
- APRE 16.13
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.